The full results of the phase III REVERSE-IT trial continue to show that ticagrelor (Brilinta)-reversing therapy bentracimab ...
The first clinical guidance for cardiogenic shock will be presented at the American College of Cardiology Scientific Session ...
Compared with standard medical care, early use of a temporary intra-aortic balloon pump (IABP) to support heart function in patients who were critically ill with cardiogenic shock caused by heart ...
Compared with standard medical care, early use of a temporary intra-aortic balloon pump (IABP) to support heart function in patients who were critically ill with cardiogenic shock caused by heart ...
Cardiogenic shock (CS) remains a significant challenge in cardiovascular medicine, characterized by substantial morbidity and mortality. Historically, patient outcomes in CS have been varied, highly ...